London: Sage Therapeutics said on Tuesday its experimental drug was found to be safe and showed some effect in patients with a rare, genetic neurological condition called Huntington's disease in a part of a mid-stage study.The company, however, said the study in Huntington's disease patients was not designed to show a statistically significant difference between the drug dalzanemdor and placebo. Shares of the company, which soared 80 per cent initially, erased those gains and were down 1.
6 per cent in volatile premarket trading.The news follows a mid-stage trial failure for the same drug, in April when it was tested in patients with Parkinson's disease. Subscribe to our newsletter to get latest insights & analysis.